Details of Drug-Drug Interaction
| Drug General Information (ID: DDIWIFLO7V) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Pentamidine | Drug Info | Insulin glulisine | Drug Info | |||||
| Drug Type | Small molecule | Hormones | |||||||
| Therapeutic Class | Antifungal Agents | Antidiabetic Agents | |||||||
| Structure | |||||||||
| Mechanism of Pentamidine-Insulin glulisine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of antidiabetic agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Pentamidine | Insulin glulisine | |||||||
| Mechanism | Direct toxic effects on beta cells of the pancreas | Antidiabetic agent | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Blood glucose should be monitored closely during and after pentamidine therapy in patients receiving insulin or other antidiabetic agents, especially if they are elderly or have renal impairment. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during pentamidine therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected. | ||||||||